MaxCyte Agrees to Acquire Akron Bio for $151.8 Million, Lines Up New $75 Million Credit Facility

MaxCyte, Inc. has entered into a definitive agreement to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management for total consideration of $151.8 million, the company announced. The transaction pairs a cash-and-stock purchase price with a newly arranged $75 million credit facility and is structured without a financing condition or a requirement for stockholder approval, according to MaxCyte's disclosures.

Deal Structure and Consideration

Under the terms disclosed by MaxCyte, the purchase price breaks into three components. At closing, MaxCyte will pay $105.0 million in cash, subject to customary adjustments, and issue 20,639,733 shares of MaxCyte common stock valued at approximately $26.8 million based on the company's closing stock price on November 9, 2026. MaxCyte will also pay $20.0 million in guaranteed deferred cash payments, split into two $10.0 million installments due on the first business day of January 2028 and January 2029.

The three components sum to the headline figure: $105.0 million in cash plus $26.8 million in stock plus $20.0 million in deferred payments equals $151.8 million, matching the total consideration MaxCyte reported. This is our calculation based on the individual payment amounts the company disclosed.

New Credit Facility and Balance Sheet Position

To support the acquisition, MaxCyte secured a new credit facility with MidCap Financial of up to $75.0 million, consisting of a $55.0 million term loan and a $20.0 million revolving credit facility. The company said that at closing it expects to draw $20.0 million under the term loan and $2.0 million under the revolver. By our calculation using those disclosed figures, that is a combined initial drawdown of $22.0 million ($20.0 million + $2.0 million), leaving $53.0 million of the $75.0 million facility undrawn ($75.0 million − $22.0 million) and available for future use.

MaxCyte stated that these initial drawdowns, together with cash on hand and the remaining availability under the facility, are expected to fund the combined company's operations through profitability. The company separately disclosed that Akron's positive EBITDA and cash flow are expected to reduce the combined company's annual cash burn to less than $10 million in 2027, with approximately $40 million to $45 million in cash expected to be on hand at closing. MaxCyte said this positions the company to reach profitability without fully utilizing the new credit facility. These are company expectations rather than guaranteed outcomes, and MaxCyte disclosed that the transaction increases its fixed obligations, including the $20.0 million in guaranteed deferred payments, and introduces new risks tied to debt service under the credit facility.

Expected Timeline

MaxCyte said the transaction is expected to close before the end of 2026, subject to customary closing conditions, a timeframe the company also repeated in its Form 8-K filing with the SEC. The company said the deal does not carry a financing condition and does not require stockholder approval, two factors that, in our reading, narrow the list of contingencies standing between signing and closing.

Strategic Rationale

Maher Masoud, President and Chief Executive Officer of MaxCyte, said the acquisition "represents a significant step forward for us, expanding our presence across the viral and non-viral cell therapy development and manufacturing workflow, while projecting to nearly double our revenue base and accelerate our path to profitability," adding that the deal "marks an exciting new chapter for MaxCyte." The revenue and profitability references are management projections disclosed in the company's announcement, not results; alongside them, MaxCyte flagged risks including integration of Akron Bio, dilution from the share issuance, increased fixed obligations from the $20.0 million of guaranteed deferred payments, and debt service under the new credit facility. Bottom line: the disclosed terms are a $151.8 million purchase funded with $105.0 million of cash at closing, 20,639,733 shares, $20.0 million of deferred payments and a $75.0 million facility that MaxCyte expects to draw on only in part, with closing targeted before the end of 2026.